This application requests continued support for the Tufts University Oncology Program to participate in the Eastern Cooperative Oncology Group. There are now 16 hospitals affiliated with New England Medical Center to form the Tufts Network, organized specifically to participate in multi-modality clinical trials. As a member of ECOG for more than 20 years, Tufts continues to provide stable leadership which encourages and facilitates patient accrual. ECOG investigators at Tufts are active in several laboratory and in-house clinical projects which will form the basis for future ECOG protocols. Sixteen Tufts network members serve on 13 ECOG disease, modality and standing steering committees. Over the past two years, Tufts Investigators have chaired 15 active or proposed ECOG studies. Tufts nurse oncologists participated in writing the drug administration sections of recent protocols and contributed to writing the Nursing Drug Information Handbook. A comprehensive data management system provides timely, accurate data collection, verified by institutional audits and central computerized delinquency monitoring. Long term goals of the Tufts Oncology Program are to increase protocol development in all treatment modalities; to translate basic science projects currently underway into ECOG protocols; to increase patient accrual on ECOG studies; to further develop and refine the data management system and to educate physicians, other medical personnel and the public about cancer clinical trials and current cancer treatment.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA007190-25
Application #
3555874
Study Section
Cancer Clinical Investigation Review Committee (CCI)
Project Start
1982-12-01
Project End
1989-04-30
Budget Start
1988-05-01
Budget End
1989-04-30
Support Year
25
Fiscal Year
1988
Total Cost
Indirect Cost
Name
Tufts University
Department
Type
Schools of Medicine
DUNS #
604483045
City
Boston
State
MA
Country
United States
Zip Code
02111
Samlowski, Wolfram E; Moon, James; Witter, Merle et al. (2017) High frequency of brain metastases after adjuvant therapy for high-risk melanoma. Cancer Med 6:2576-2585
Flaherty, Lawrence E; Othus, Megan; Atkins, Michael B et al. (2014) Southwest Oncology Group S0008: a phase III trial of high-dose interferon Alfa-2b versus cisplatin, vinblastine, and dacarbazine, plus interleukin-2 and interferon in patients with high-risk melanoma--an intergroup study of cancer and leukemia Group B, Ch J Clin Oncol 32:3771-8
Ganz, Patricia A; Land, Stephanie R; Geyer Jr, Charles E et al. (2011) Menstrual history and quality-of-life outcomes in women with node-positive breast cancer treated with adjuvant therapy on the NSABP B-30 trial. J Clin Oncol 29:1110-6
Swain, Sandra M; Jeong, Jong-Hyeon; Geyer Jr, Charles E et al. (2010) Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer. N Engl J Med 362:2053-65
Landry, Jerome; Catalano, Paul J; Staley, Charles et al. (2010) Randomized phase II study of gemcitabine plus radiotherapy versus gemcitabine, 5-fluorouracil, and cisplatin followed by radiotherapy and 5-fluorouracil for patients with locally advanced, potentially resectable pancreatic adenocarcinoma. J Surg Oncol 101:587-92
Hughes, Lorie L; Wang, Molin; Page, David L et al. (2009) Local excision alone without irradiation for ductal carcinoma in situ of the breast: a trial of the Eastern Cooperative Oncology Group. J Clin Oncol 27:5319-24
Horn, Leora; Dahlberg, Suzanne E; Sandler, Alan B et al. (2009) Phase II study of cisplatin plus etoposide and bevacizumab for previously untreated, extensive-stage small-cell lung cancer: Eastern Cooperative Oncology Group Study E3501. J Clin Oncol 27:6006-11
Greenberg, Peter L; Sun, Zhuoxin; Miller, Kenneth B et al. (2009) Treatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte colony-stimulating factor: results of a prospective randomized phase 3 trial by the Eastern Cooperative Oncology Group (E1996). Blood 114:2393-400
Souphron, Judith; Waddell, M Brett; Paydar, Amir et al. (2008) Structural dissection of a gating mechanism preventing misactivation of ubiquitin by NEDD8's E1. Biochemistry 47:8961-9
Byrd, John C; Rai, Kanti; Peterson, Bercedis L et al. (2005) Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. Blood 105:49-53

Showing the most recent 10 out of 30 publications